Dyne Therapeutics Inc
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal mus… Read more
Dyne Therapeutics Inc - Asset Resilience Ratio
Dyne Therapeutics Inc (DYN) has an Asset Resilience Ratio of 18.30% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2025)
This chart shows how Dyne Therapeutics Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Dyne Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $217.19 Million | 18.3% |
| Total Liquid Assets | $217.19 Million | 18.30% |
Asset Resilience Insights
- Good Liquidity Position: Dyne Therapeutics Inc maintains a healthy 18.30% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Dyne Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Dyne Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Dyne Therapeutics Inc (2007–2025)
The table below shows the annual Asset Resilience Ratio data for Dyne Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 18.30% | $217.19 Million | $1.19 Billion | -11.62pp |
| 2024-12-31 | 29.92% | $206.82 Million | $691.23 Million | +29.03pp |
| 2023-12-31 | 0.89% | $1.47 Million | $165.08 Million | -26.48pp |
| 2022-12-31 | 27.38% | $83.86 Million | $306.32 Million | -13.91pp |
| 2021-12-31 | 41.29% | $175.75 Million | $425.66 Million | +28.70pp |
| 2020-12-31 | 12.58% | $44.46 Million | $353.33 Million | +12.31pp |
| 2017-12-31 | 0.27% | $32.00 Million | $11.77 Billion | -0.72pp |
| 2016-12-31 | 1.00% | $130.00 Million | $13.05 Billion | +0.13pp |
| 2015-12-31 | 0.87% | $100.00 Million | $11.54 Billion | +0.17pp |
| 2014-12-31 | 0.69% | $78.00 Million | $11.23 Billion | +0.22pp |
| 2013-12-31 | 0.47% | $25.00 Million | $5.29 Billion | +0.19pp |
| 2012-12-31 | 0.29% | $13.00 Million | $4.54 Billion | -1.39pp |
| 2011-12-31 | 1.67% | $69.00 Million | $4.13 Billion | +0.61pp |
| 2010-12-31 | 1.06% | $106.00 Million | $10.01 Billion | +0.35pp |
| 2009-12-31 | 0.71% | $78.00 Million | $10.95 Billion | +0.10pp |
| 2008-12-31 | 0.61% | $87.00 Million | $14.21 Billion | -0.17pp |
| 2007-12-31 | 0.79% | $104.00 Million | $13.22 Billion | -- |